Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000093357

Apexbio Technology LLC Thalidomide-O-amido-C4-NH2 TFA 1799711-25-3 50mg
SDP

Catalog No. 5000093357
Encompass_Preferred

Thalidomide-O-amido-C4-NH2 TFA (CAS 1799711-25-3) is a synthetic small molecule composed of a thalidomide-derived cereblon ligand conjugated to a chemical linker This compound selectively binds to cereblon (CRBN) a substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex By facilitating the recruitment of target proteins to the CRBN complex it enables their ubiquitination and subsequent proteasomal degradation Thalidomide-O-amido-C4-NH2 TFA serves as a molecular tool in the development of proteolysis targeting chimeras (PROTACs) and other targeted protein degradation strategies in biomedical research

Catalog No. 50-000-93357 Supplier Apexbio Technology LLC Supplier No. A998450
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Thalidomide-O-amido-C4-NH2 TFA (CAS 1799711-25-3) is a synthetic small molecule composed of a thalidomide-derived cereblon ligand conjugated to a chemical linker This compound selectively binds to cereblon (CRBN) a substrate receptor of the CRL4CRBN E3 ubiquitin ligase complex By facilitating the recruitment of target proteins to the CRBN complex it enables their ubiquitination and subsequent proteasomal degradation Thalidomide-O-amido-C4-NH2 TFA serves as a molecular tool in the development of proteolysis targeting chimeras (PROTACs) and other targeted protein degradation strategies in biomedical research

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.